Actuate Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement

On July 15, 2026, Actuate Therapeutics, Inc. received a deficiency notice from the Nasdaq Listing Qualifications Department. The notice informed the Company that it is no longer in compliance with Nasdaq Listing Rule 5450(b)(2)(A) because its Market Value of Listed Securities (MVLS) fell below the minimum requirement of $50 million for 30 consecutive business days (specifically from June 1, 2026, to July 14, 2026). The notice does not result in the immediate delisting of the Company's common stock, which continues to trade under the symbol 'ACTU'. Actuate has been granted a 180-day compliance period, ending on January 11, 2027, to regain compliance. To do so, the Company's MVLS must close at $50 million or higher for at least ten consecutive business days. If compliance is not achieved by the deadline, the Company may face delisting, though it would have the right to appeal or apply for a transfer to The Nasdaq Capital Market. The Company intends to monitor its MVLS and explore measures to regain compliance.